ADAR1 Capital Management LLC Lowers Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

ADAR1 Capital Management LLC trimmed its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 29.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 177,707 shares of the company’s stock after selling 73,693 shares during the quarter. ADAR1 Capital Management LLC owned 0.09% of Taysha Gene Therapies worth $307,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Wells Fargo & Company MN boosted its stake in shares of Taysha Gene Therapies by 43.7% during the fourth quarter. Wells Fargo & Company MN now owns 103,384 shares of the company’s stock valued at $179,000 after purchasing an additional 31,457 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Taysha Gene Therapies by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company’s stock valued at $6,182,000 after acquiring an additional 9,591 shares during the period. Wellington Management Group LLP lifted its stake in shares of Taysha Gene Therapies by 26.4% during the 4th quarter. Wellington Management Group LLP now owns 585,594 shares of the company’s stock worth $1,013,000 after purchasing an additional 122,402 shares during the last quarter. Norges Bank bought a new position in Taysha Gene Therapies in the fourth quarter worth about $2,528,000. Finally, EntryPoint Capital LLC grew its position in shares of Taysha Gene Therapies by 127.5% in the 4th quarter. EntryPoint Capital LLC now owns 61,495 shares of the company’s stock worth $106,000 after buying an additional 34,468 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Analyst Ratings Changes

TSHA has been the subject of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, February 27th. Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Stock Down 3.2 %

Shares of TSHA opened at $1.22 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The stock has a market capitalization of $250.10 million, a PE ratio of 1.94 and a beta of 0.96. The company’s 50-day simple moving average is $1.63 and its 200-day simple moving average is $1.88. Taysha Gene Therapies, Inc. has a 1 year low of $1.17 and a 1 year high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The business had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $2.05 million. Analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.